Skip to main content
. Author manuscript; available in PMC: 2021 Nov 4.
Published in final edited form as: J Alzheimers Dis. 2021;82(2):689–699. doi: 10.3233/JAD-210252

Table 4.

Longitudinal association of systolic blood pressure with cognition change at a 5-year follow-up (N = 830)

Cognitive domains (Beta 95% CI, per 10 mmHg SBP)
Episodic memory Processing speed/VMI
Hypertension meds + +
Model 1 −0.0134 (−0.0443, 0.0175) −0.0129 (−0.0446; 0.0188) −0.0243 (−0.0495, 0.0008) −0.0200 (−0.0457; 0.0057)
Model 2 −0.0222 (−0.0540, 0.0097) −0.0206 (−0.0532; 0.0121) −0.0262 (−0.0520, −0.0006)* −0.0219 (−0.0481; 0.0044)
Model 3 −0.0200 (−0.0517, 0.0117) −0.0190 (−0.0514; 0.0135) −0.0258 (−0.0515, −0.00004)* −0.0215 (−0.0477; 0.0047)
Model 4 −0.0193 (−0.0513, 0.0127) −0.0184 (−0.0512; 0.0143) −0.0290 (−0.0555, −0.0025)* −0.0239 (−0.0509; 0.0031)
Word fluency/semantic memory Executive function
Hypertension meds + +
Model 1 −0.0113 (−0.0362, 0.0137) −0.0131 (−0.0386; 0.0124) 0.0142 (−0.0162, 0.0447) 0.0156 (−0.0156; 0.0468)
Model 2 −0.0150 (−0.0408, 0.0108) −0.0156 (−0.0419; 0.0107) 0.0189 (−0.0123, 0.0501) 0.0197 (−0.0122; 0.0517)
Model 3 −0.0138 (−0.0395, 0.0119) −0.0148 (−0.0410; 0.0114) 0.0195 (−0.0118, 0.0507) 0.0202 (−0.0118; 0.0522)
Model 4 −0.0149 (−0.0414, 0.0116) −0.0161 (−0.0431; 0.0109) 0.0183 (−0.0136, 0.0502) 0.0170 (−0.0158; 0.0497)
*

p≤0.05

**

p≤0.01

***

p<0.001.

Model 1: adjusted for age, education, sex, race-ethnicity, APOE genotype with/without anti-hypertension medications. Model 2: model 2 additionally adjusted for BMI, smoking status, blood glucose, and cholesterol levels with/without anti-hypertension medications. Model 3: model 3 additionally adjusted for white matter hyperintensity volume (WMHV) corrected by total cranial volume, with/without anti-hypertension medications. Model 4: model 4 additionally adjusted for total carotid artery intima media thickness (cIMT), with/without anti-hypertension medications.